Cytokinetics (CYTK) Long-Term Investments (2010 - 2026)

Cytokinetics (CYTK) has reported Long-Term Investments for 15 consecutive years, with $254.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments rose 69.04% year-over-year to $254.7 million; the TTM figure through Mar 2026 stood at $254.7 million (up 69.04% YoY), while the FY2025 annual figure was $335.0 million, up 130.98% from the prior year.
• Long-Term Investments eased to $254.7 million in Q1 2026 per CYTK's latest filing, from $335.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $335.0 million in Q4 2025 and bottomed at $10.7 million in Q2 2022.
• Historically, Long-Term Investments has averaged $131.1 million across 5 years, with a median of $77.1 million in 2022.
• Annual changes were most pronounced in 2022 — Long-Term Investments tumbled 85.52% — and 2024, when it jumped 1640.16%.
• Cytokinetics' Long-Term Investments stood at $46.7 million in 2022, then slipped by 13.22% to $40.5 million in 2023, then jumped by 257.86% to $145.1 million in 2024, then jumped by 130.98% to $335.0 million in 2025, then fell by 23.98% to $254.7 million in 2026.
• Business Quant data shows CYTK's Long-Term Investments at $254.7 million in Q1 2026, $335.0 million in Q4 2025, and $288.8 million in Q3 2025.